Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from AstraZeneca

AstraZeneca to invest $2.5bn in drugs research and manfacturing in Beijing

Pharma company will invest money over five years in ‘strategic partnership’ after ditching UK expansion

The Guardian - UK

AstraZeneca pays up to $1bn for biotech firm ‘that could transform cell therapy’

UK pharma group acquires Belgium’s EsoBiotec as it announces EU has approved Imfinzi lung cancer drug

The Guardian - UK

AstraZeneca Stock Nears Buy Point After Long Run In Declining Market

This biopharmaceutical stock is nearing a buy point of a cup-with-handle base.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Inside The Quantum Computing Crash Triggered By Nvidia CEO — And What His Upcoming 'Quantum Day' May Bring

Quantum computing stocks crashed after Nvidia's CEO comments. Will Nvidia's 'Quantum Day' change the outlook?

Investors Business Daily

GSK could double CEO Emma Walmsley's pay to $27 million

The British pharma giant said Emma Walmsley's current pay could put off candidates for her eventual successor.

Fortune

Yale Scientists Link Covid Vaccines To Alarming New Syndrome With Long-Term Effects

"It's like being drained of vitality." Scientists discovered a new syndrome linked to the COVID-19 vaccines that may cause persistent biological changes and chronic flu-like symptoms. The post Yale Scientists Link Covid Vaccines To Alarming New Syndrome With Long-Term Effects first appeared on Bored Panda.

Bored Panda

AstraZeneca boss takes home £15m pay packet after profits rise

The Cambridge-based pharmaceutical company behind a variety of medicines paid its chief executive Pascal Soriot £14.7 million in 2024.

Evening Standard

Read news from The Economist, FT, and more,
with one subscription

Why Most Pharma Startups Fail—And How Barbara Navarro Strategic Consulting is Turning Struggles into Success

The pharmaceutical and biotech industries are brimming with potential. From revolutionary cancer treatments to cutting-edge gene-editing breakthroughs, start-ups in this space have the power to transform medicine and save lives.

inkl

AstraZeneca, Whitehall, and a failed £450m deal for the next generation in vaccines. What went wrong?

When the pharma firm cancelled plans for a major expansion of its Merseyside plant last month, there was no shortage of questions – or blame – over responsibility

The Guardian - UK

Inside AstraZeneca’s abandoned UK vaccine plant deal as Labour and Tories face questions over £450m collapse

AstraZeneca’s planned vaccine hub for Liverpool is off the table - business editor Karl Matchett and Whitehall editor Kate Devlin question why it fell through

The Independent UK

FTSE 100 notches new record after Bank of England cuts rates

London’s blue-chip index smashed through recent highs after experts said the Bank’s announcement gave it ‘a shot of adrenaline’.

The Independent UK

AstraZeneca Could Pay $4.5 Million In China Scandal. Here's Why Shares Jumped.

AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.

Investors Business Daily

Dow Jones Rises After Surprise Jobless Claims; Roblox Crashes 30% On Sales Miss

The Dow Jones rose Thursday after surprise weekly jobless claims. Nvidia partner Arm stock tumbled on earnings, while Roblox crashed.

Investors Business Daily

AstraZeneca ‘very disappointed’ after ditching £450m Liverpool vaccine site

Pascal Soriot, chief executive of AstraZeneca, denied any rift with the Government over the decision.

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

AstraZeneca ‘very disappointed’ over axed £450m Liverpool vaccine project

As drugmaker reports 38% jump in profits, CEO denies tension with UK government after Speke plant decision

The Guardian - UK

Blame ministers for AstraZeneca U-turn

Letters: As a health minister in the 1970s, David Owen writes, he would have been too close to industry to allow such a deal to fail

The Guardian - UK

AstraZeneca’s U-turn on £450m Speke expansion ‘deeply disappointing’, says minister

Chris Bryant says reduction of government support was linked to change in drugmaker’s proposed investment

Evening Standard

AstraZeneca investment deal ‘didn’t add up for UK taxpayer’, says minister

Science minister Sir Chris Bryant said the Government feels regretful about the plan being ditched and ‘would prefer to have got this over the line’.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

AstraZeneca’s £450m Speke U-turn looks terrible for a pro-growth government

It seems bizarre that ministers and UK’s largest company cannot complete investment in vital life sciences sector

Evening Standard

What the papers say – February 1

Here are the major stories grabbing the attention on Saturday’s news stands.

The Guardian - UK

What has the UK Covid inquiry learned so far about vaccines and treatments?

In fourth part of the inquiry, questons were asked about vaccine trials, procurement and the UK’s preparedness for future pandemics

The Independent UK

Fresh blow for Rachel Reeves as AstraZeneca scraps £450m investment in UK vaccine plant

The pharmaceutical giant claimed the Labour Government failed to match its predecessor’s offer but the cancelled project is a blow to the chancellor’s growth agenda

Evening Standard

AstraZeneca cancels £450m vaccine plant in UK after Government 'own goal' in blow to Rachel Reeves growth plan

The pharmaceutical giant claimed the Labour Government failed to match Tory predecessor’s offer of help for its investment in Merseyside

The Guardian - UK

AstraZeneca axes £450m vaccine plant in Liverpool, blaming state funding cut

Days after Rachel Reeves highlighted life sciences as UK strength, firm decides against site expansion

Barchart

Up 1,000% in 2024, Wall Street Believes This Growth Stock Can Still Skyrocket

This biotech stock is a promising buy, but it does come with risks.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.